Drugs / [68Ga]Ga-NODAGA-SNA014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06646783 | Oct 2024 → Oct 2025 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm | SmartNuclide Biopharma | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-NODAGA-SNA014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06646783 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction” NCT06646783 ↗ |